Genprex Faces Potential Delisting Concerns
Ticker: GNPX · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1595248
Sentiment: bearish
Topics: delisting, compliance, exchange-rules
Related Tickers: GNPX
TL;DR
Genprex might be delisted - big trouble ahead.
AI Summary
Genprex, Inc. filed an 8-K on February 12, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filing indicates potential issues with maintaining its listing on the stock exchange, though specific details regarding the rule or standard not met are not elaborated in this summary.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could significantly impact investor confidence and the company's ability to raise capital.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's public trading status, creating significant uncertainty and risk for investors.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- 0001595248 (company) — Central Index Key
- 001-38244 (company) — SEC File Number
- 900772347 (company) — IRS Number
- February 7, 2025 (date) — Date of earliest event reported
- February 12, 2025 (date) — Date of report
FAQ
What specific listing rule or standard has Genprex, Inc. failed to satisfy?
The provided filing summary does not specify the exact listing rule or standard that Genprex, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy such a rule has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 7, 2025.
What is the SEC file number for Genprex, Inc.?
The SEC file number for Genprex, Inc. is 001-38244.
What is the principal executive office address for Genprex, Inc.?
The principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.
What is the filing date of this Form 8-K?
This Form 8-K was filed on February 12, 2025.
Filing Stats: 1,131 words · 5 min read · ~4 pages · Grade level 13.1 · Accepted 2025-02-12 08:15:20
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
- $1.00 — ment to maintain a minimum bid price of $1.00 per share for continued listing on The
- $2.5 million — are as follows: the Company must report $2.5 million in stockholders' equity in its Quarterl
Filing Documents
- gnpx20250203_8k.htm (8-K) — 31KB
- 0001437749-25-003490.txt ( ) — 165KB
- gnpx-20250207.xsd (EX-101.SCH) — 3KB
- gnpx-20250207_def.xml (EX-101.DEF) — 12KB
- gnpx-20250207_lab.xml (EX-101.LAB) — 15KB
- gnpx-20250207_pre.xml (EX-101.PRE) — 12KB
- gnpx20250203_8k_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 7, 2025, Genprex, Inc. (the "Company") received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market ("Nasdaq") notifying the Company that, based upon the closing bid price of the Company's common stock, par value $0.001 per share ("Common Stock"), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Nasdaq notification has no immediate effect on the listing or trading of the Company's Common Stock on The Nasdaq Capital Market, and, therefore, the Company's listing remains fully effective. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until August 6, 2025 (the "Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. If, at any time during this 180-day period, the closing bid price of the Company's Common Stock is at least $1.00 for a minimum of 10 consecutive business days, subject to the Staff's discretion to extend such 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H), the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement and the matter will be closed. If the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period. To qualify for such additional compliance period, the Company would have to (i) meet the continued listing requirement for market value of publicly held shares and all other initial listing standards of The Nasdaq Capital Market, except for the Minimum Bid Price Requirement, and (ii) provide writte
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: February 12, 2025 By: /s/ Ryan M. Confer Ryan M. Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)